Indication
Berylliosis
Berylliosis, also known as chronic beryllium disease, is an occupational pulmonary and systemic granulomatous disorder caused by the inhalation of beryllium dusts, fumes, or salts. Read more about Berylliosis
334 drugs 161 manufacturers
Drugs that treat it
Common Berylliosis therapies.
DEXABLISS (dexamethasone)
ZCORT (dexamethasone)
RAYOS (prednisone)
CELESTONE SOLUSPAN (betamethasone acetate/betamethasone sodium phosphate)
DEPO-MEDROL (methylprednisolone acetate)
MEDROL (PAK) (methylprednisolone)
MILLIPRED (prednisolone)
SOLU-MEDROL (PF) (methylprednisolone sodium succinate/PF)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonBerylliosis, also known as chronic beryllium disease, is an occupational pulmonary and systemic granulomatous disorder caused by the inhalation of beryllium dusts, fumes, or salts.
It primarily affects the respiratory system of individuals exposed in manufacturing, aerospace, ceramics, electronics, and metallurgy industries.
Pathophysiologically, the disease is driven by a beryllium-specific, cell-mediated type IV hypersensitivity response in genetically susceptible individuals, leading to persistent lymphocytic infiltration and noncaseating epithelioid granuloma formation that closely mimics sarcoidosis.
Clinically, affected patients experience a gradual onset of exertional dyspnea, persistent dry cough, fatigue, chest pain, and weight loss, which may progressively lead to restrictive pulmonary impairment, interstitial fibrosis, and cor pulmonale.
- nih.gov
Berylliosis, also known as chronic beryllium disease, is an occupational pulmonary and systemic granulomatous disorder caused by the inhalation of beryllium dusts, fumes, or salts Clinically, affected patients experience a gradual onset of exertional dyspnea, persistent dry cough, fatigue, chest pain, and weight loss, which may progressively lead to restrictive pulmonary impairment, interstitial fibrosis, and cor pulmonale
- cdc.gov
Berylliosis, also known as chronic beryllium disease, is an occupational pulmonary and systemic granulomatous disorder caused by the inhalation of beryllium dusts, fumes, or salts Pathophysiologically, the disease is driven by a beryllium-specific, cell-mediated type IV hypersensitivity response in genetically susceptible individuals, leading to persistent lymphocytic infiltration and noncaseating epithelioid granuloma formation that closely mimics sarcoidosis Clinically, affected patients exper...
- cdc.gov
Berylliosis, also known as chronic beryllium disease, is an occupational pulmonary and systemic granulomatous disorder caused by the inhalation of beryllium dusts, fumes, or salts
- nih.gov
It primarily affects the respiratory system of individuals exposed in manufacturing, aerospace, ceramics, electronics, and metallurgy industries
- cdc.gov
It primarily affects the respiratory system of individuals exposed in manufacturing, aerospace, ceramics, electronics, and metallurgy industries Pathophysiologically, the disease is driven by a beryllium-specific, cell-mediated type IV hypersensitivity response in genetically susceptible individuals, leading to persistent lymphocytic infiltration and noncaseating epithelioid granuloma formation that closely mimics sarcoidosis
- cdc.gov
It primarily affects the respiratory system of individuals exposed in manufacturing, aerospace, ceramics, electronics, and metallurgy industries
- nih.gov
Pathophysiologically, the disease is driven by a beryllium-specific, cell-mediated type IV hypersensitivity response in genetically susceptible individuals, leading to persistent lymphocytic infiltration and noncaseating epithelioid granuloma formation that closely mimics sarcoidosis
Personalize your experience
Follow Berylliosis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.